ArticleMolecular and clinical oncology2025
AEG-1 expression analysis in epithelial ovarian carcinoma: Uncovering distinctions between high-grade and low-grade serous carcinoma.
Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian carcinoma (EOC) is the most common form of ovarian cancer and is associated with a poor prognosis. Astrocyte Elevated Gene-1 (AEG-1) is an oncogene implicated in cancer cell growth and progression. The present study examined AEG-1 expression in EOC, specifically comparing high-grade serous ovarian carcinoma (HGSOC) and low-grade serous ovarian carcinoma (LGSOC). The present retrospective analytical study employed a cross-sectional design and included women diagnosed with HGSOC or LGSOC between January 2021 and December 2023. Extracted data included demographic, laboratory and clinicopathological characteristics. In addition to comparing AEG-1 expression in HGSOC and LGSOC, associations between these histological subtypes and the extracted variables, as well as associations between AEG-1 expression and these variables, were assessed. Of the 74 patients initially identified, 24 were excluded, resulting in a final sample of 50 patients 23 with LGSOC and 27 with HGSOC. A statistically significant association was found between residual disease and cancer histopathology [odds ratio: 7.219; 95% confidence interval (CI): 1.399-37.252; P=0.024), whereas no significant associations were observed with other variables. AEG-1 expression was significantly higher in HGSOC compared with LGSOC (relative risk: 3.228; 95% CI: 1.188-8.776; P=0.012), with high AEG-1 expression observed more frequently in HGSOC (65.7%) than in LGSOC (34.3%). In conclusion, AEG-1 expression was significantly elevated in HGSOC compared with LGSOC, suggesting a potential role for AEG-1 in the progression of HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.